首页> 美国卫生研究院文献>Scientific Reports >Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment
【2h】

Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment

机译:使用新型抗LPS scFv抗体片段抑制土拉弗朗西斯菌的吞噬作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Francisella tularensis (Ft), the causative agent of lethal tularemia, is classified as a category A biological warfare threat agent. While Ft infection is treatable by antibiotics, many failed antibiotic treatments were reported, highlighting the need for effective new treatments. It has been demonstrated that binding of antibody-coated bacteria to the Fc receptor located on phagocytic cells is a key process needed for efficient protection against Ft. Yet, Ft utilizes the same receptor to enter the phagocytic cells in order to escape the immune system. To address the question whether an anti-Ft LPS antibody lacking the ability to bind the Fc receptor may inhibit the entry of Ft into host cells, a soluble scFv (TL1-scFv) was constructed from an anti Ft-LPS antibody (TL1) that was isolated from an immune single-chain (scFv) phage-display library. Bacterial uptake was assessed upon infection of macrophages with Ft live attenuated strain (LVS) in the presence of either TL1 or TL1-scFv. While incubation of LVS in the presence of TL1 greatly enhanced bacterial uptake, LVS uptake was significantly inhibited in the presence of TL1-scFv. These results prompt further experiments probing the therapeutic efficacy of TL1-scFv, alone or in combination with antibiotic treatment.
机译:致命性Tularemia的病原体Francisella tularensis(Ft)被列为A类生物战威胁因子。虽然Ft感染可以用抗生素治疗,但据报道许多抗生素治疗失败,这突出表明需要有效的新疗法。已经证明,抗体包被的细菌与位于吞噬细胞上的Fc受体的结合是有效保护Ft所需的关键过程。然而,Ft利用相同的受体进入吞噬细胞,以逃避免疫系统。为了解决缺乏结合Fc受体能力的抗Ft LPS抗体是否可以抑制Ft进入宿主细胞的问题,从抗Ft-LPS抗体(TL1)构建了可溶性scFv(TL1-scFv),从免疫单链(scFv)噬菌体展示文库中分离得到。在存在TL1或TL1-scFv的情况下,巨噬细胞被Ft活减毒株(LVS)感染后,评估细菌的摄取。虽然在TL1存在下孵育LVS可以大大提高细菌的摄取,但是在TL1-scFv存在下LVS的摄取却被显着抑制。这些结果促使进一步的实验探索单独或与抗生素治疗组合的TL1-scFv的治疗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号